Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 3 1Phase 1 1

Status

Completed 3Active not recruiting 3Terminated 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 119Specimen Handling 104pembrolizumab 102Magnetic Resonance Spectroscopy 96fludarabine 92Biopsy 79Injections 53Nivolumab 41venetoclax 40Bevacizumab 40Fluorouracil 38Paclitaxel 37Cisplatin 36Cetuximab 35Carboplatin 35Gemcitabine 31fludarabine phosphate 30Radiotherapy 30Oxaliplatin 30Leucovorin 28Immunotherapy, Adoptive 25Drug Therapy 25Ipilimumab 24Azacitidine 23Irinotecan 21130-nm albumin-bound paclitaxel 21tislelizumab 20Temozolomide 20Radiation 20atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × belantamab mafodotin × Clear all
NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡